Ernexa Therapeutics Inc. Earnings Per Share Disclosure
| 14) | Basic and Diluted Net Loss per Common Share |
| Years ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Numerator: | ||||||||
| Net loss attributable to common stockholders | $ | (44,555 | ) | $ | (21,684 | ) | ||
| Denominator: | ||||||||
| Weighted average shares outstanding - basic and diluted | ||||||||
| Net loss per common share - basic and diluted | $ | ) | $ | ) | ||||
Since the Company was in a net loss position for all periods presented, the net loss per share attributable to common stockholders was the same on a basic and diluted basis, as the inclusion of all potential common equivalent shares outstanding would have been anti-dilutive.
| Years ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Stock options | 2,629 | 389 | ||||||
| Warrants | 484 | 18,922 | ||||||
| Preferred stock converted into common stock | 31 | 18 | ||||||
| Convertible Notes converted into common stock | 7,877 | |||||||
| RSUs | 1 | |||||||
| Total potential common shares excluded from computation | 3,144 | 27,207 | ||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.